Indeed, CD38 monoclonal antibodies have shown high efficacies in multiple myeloma at different lines of therapy, which is exerted through both antibody-mediated cytotoxicity, as well as modulation of immune surveillance in the niche11,12. This evidence concerns the gene CD38 and AL amyloidosis.